PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Cost reduction while TRVN shows 9.09% growth. Joel Greenblatt would examine competitive advantage.
12.50%
Gross profit growth below 50% of TRVN's 185.26%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
37.48%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
21.30%
G&A change of 21.30% while TRVN maintains overhead. Bruce Berkowitz would investigate efficiency.
100.00%
Marketing expense change of 100.00% while TRVN maintains spending. Bruce Berkowitz would investigate effectiveness.
No Data
No Data available this quarter, please select a different quarter.
32.37%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
29.39%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
D&A reduction while TRVN shows 1.14% growth. Joel Greenblatt would examine efficiency.
-30.36%
EBITDA decline while TRVN shows 39.95% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-29.39%
Operating income decline while TRVN shows 34.17% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
14.89%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
-30.95%
Pre-tax income decline while TRVN shows 36.70% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing tax expense. Martin Whitman would check patterns.
-30.95%
Net income decline while TRVN shows 36.30% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-22.58%
EPS decline while TRVN shows 36.29% growth. Joel Greenblatt would examine position.
-22.58%
Diluted EPS decline while TRVN shows 36.29% growth. Joel Greenblatt would examine position.
7.95%
Share count reduction below 50% of TRVN's 0.07%. Michael Burry would check for concerns.
7.95%
Diluted share reduction below 50% of TRVN's 0.07%. Michael Burry would check for concerns.